Novel Targets for IBD Therapy:
Is This the Final Frontier?

Novel Targets for IBD Therapy: Is This the Final Frontier?

A satellite symposium held in conjunction with the 2017 Advances in Inflammatory Bowel Diseases: Multidisciplinary Approaches to IBD Patient-Centered Care conference.

Friday, November 10, 2017
Northern Hemisphere Ballroom, C-D
12:45 pm – 1:45 PM
Support by: Pfizer

Chair
Miguel D. Regueiro, MD, FACG
University of Pittsburgh
School of Medicine
Pittsburgh, Pennsylvania

REGISTER NOW

 

Organizer

Imedex
11675 Rainwater Drive, Suite 600
Alpharetta, GA 30009, USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
Web: www.imedex.com
FacebookTwitterLinkedInEmail

Accreditation

ACCMEImedex is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

Imedex designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification (MOC)

Successful completion of this CME activity enables a participant to earn up to 1.0 MOC point towards the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is Imedex’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC Points.

Who Should Attend

This live activity is designed to meet the educational needs of Physicians, surgeons, nurse practitioners, pharmacists, physician assistants, nurses, and other healthcare professionals who are involved and/or interested in the treatment of patients with IBD.

Learning Objectives

After successful completion of the recommended education, participants should be able to:

  • Analyze mechanism of action and safety-efficacy profiles of newer IBD drugs
  • Implement the rational use of current and emerging therapies in case-based scenarios
  • Interpret pivotal clinical study data for translating in day-to-day practice

Agenda

12:40 pm

Welcome and pre-activity survey
Miguel D. Regueiro, MD, FACG

12:45 pm

Positioning of biologics and new therapeutics for ulcerative colitis
Corey A. Siegel, MD, MS

12:55 pm

Patient case Discussion: Patient with moderate to severe ulcerative colitis
Miguel D. Regueiro, MD, FACG

1:10 pm

Positioning of biologics and new therapeutics for Crohn’s disease
Marla Dubinsky, MD

1:20 pm

Patient case discussion: Patient with moderate to severe Crohn’s disease
Miguel D. Regueiro, MD, FACG

1:35 pm

Summary and post-test questions
Miguel D. Regueiro, MD, FACG

1:40 pm

Adjourn

Faculty

Marla Dubinsky, MD
Icahn School of Medicine at Mount Sinai
New York, New York

Miguel D. Regueiro, MD, FACG
University of Pittsburgh
School of Medicine
Pittsburgh, Pennsylvania

Corey A. Siegel, MD, MS
Dartmouth-Hitchcock Medical Center
Geisel School of Medicine Lebanon, New Hampshire

Support

The following company has provided an educational grant in support of this symposium: Pfizer.

Registration

Registration Fees
Registration is complimentary to those registered to attend the Advances in Inflammatory Bowel Diseases: Multidisciplinary Approaches to IBD Patient-Centered Care conference.

Location

Conference Location and Hotel Accommodations
Walt Disney World Dolphin Hotel
1500 Epcot Resorts Boulevard
Lake Buena Vista, Florida 32838
Tel.: +1 (407) 934 4000
http://www.swandolphin.com/home.html

Available seating will be based on room capacity. Seating is limited and pre-registration is for planning purposes only and does not guarantee admission, as the room may be overbooked. Early arrival is recommended and seating will be first-come first-serve until capacity is met.

The Registration and Information Desk at the Norther Hemisphere Foyer will be staffed:
Friday, November 10, 2017      12:15 pm – 2:15 pm